Global Classical Swine Fever Vaccines Market 2026 – 2035
Report Overview
The global market for classical swine fever vaccines is estimated at USD 1.24 billion in 2025 and is projected to increase from USD 1.34 billion in 2026 to approximately USD 2.87 billion by 2035, a 8.3% CAGR from 2026 to 2035.
.webp)
Market Highlights
- Asia-Pacific held the maximum share in 2025 with 42%, with the highest number of swine, frequent outbreaks and significant government funding for livestock disease control.
- Europe is expected to show the fastest CAGR during 2026-2035 due to strict regulations, mandatory vaccinations and vaccine formulation technologies.
- Inactivated vaccines accounted for around 51% of the market in 2025, the most commonly adopted and regulated format.
- Chimeric/DIVA vaccine types are growing at the fastest CAGR of 12.4%, driven by DIVA capability and rising approvals.
- Intramuscular injection accounted for around 58% in 2025.
- Livestock farms were the top end user with a 67% share in 2025.
Significant Growth Factors
- Rising Swine Production and Intensification: Global swine numbers (~1.51 billion in 2024, projected ~1.78 billion by 2035), especially in China, Vietnam and India, drive sustained vaccination demand as intensified production raises biosecurity risk.
- Regulatory Mandates and Eradication Programs: EU, US and Asia-Pacific vaccination mandates and eradication goals create multi-year demand visibility. Regulatory-mandated programs make up about 34% of vaccines consumed worldwide.
Major Advances Changing the Market
- DIVA-Compliant Vaccines: Vaccines that differentiate infected from vaccinated animals let countries vaccinate without losing disease-free export certification; approved in the EU (E2 deletion) and Canada, with 6-12% price premiums.
- Improved Thermostability: Formulations stable at up to 25°C reduce cold-chain needs and cut storage costs 35-50%, helping the ~75% of swine farmers who are small-scale.
- Recombinant and Nanoparticle Platforms: Safer profiles, longer immunity (12-18 months) and higher immunogenicity; advanced-platform adoption projected at ~15.2% CAGR.
Category Wise Insights
By Vaccine Type
Inactivated vaccines led with ~51% of 2025 revenue on the basis of regulatory approval, decades of use, safety and compatibility with farm biosecurity (85-95% protection; USD 0.80-2.50 per dose).
By Delivery Method
Intramuscular injection accounted for 58% of the market in 2025 due to infrastructure compatibility, reliable seroconversion, regulatory precedent (89% of approved products) and cost. Oral delivery grows at 13.2% CAGR, mainly for wild boar programs.
By End User
Livestock farms led with 67% in 2025, concentrated in commercial operations. Veterinary clinics account for 22%, serving small-scale and backyard farmers.
Report Scope
| Feature | Details |
|---|---|
| Market Size in 2026 | USD 1.34 billion |
| Projected Market Size in 2035 | USD 2.87 billion |
| Market Size in 2025 | USD 1.24 billion |
| CAGR | 8.3% |
| Base Year | 2025 |
| Forecast Period | 2026-2035 |
| Regional Scope | North America, Europe, Asia Pacific, MEA, South & Central America |
Regional Analysis
.webp)
Asia-Pacific
Asia Pacific market size is expected to reach USD 521 million by 2025 and USD 1.23 billion by 2035 at a 9.2% CAGR. The region has ~64% of swine populations and 42% of global revenue; China has the largest number of pigs (436 million).
Europe
Europe represents 28% of global revenue (~USD 347 million in 2025) with the most demanding animal health legislation; 73% of global DIVA vaccine candidates are in European regulatory review.
Fastest-Growing
Asia-Pacific shows the highest CAGR at 11.7% during 2026-2035, driven by post-ASF production recovery, disease-control awareness and vaccine access.
Europe and North America Premium Markets
Europe and North America account for 35% share and the highest price-per-dose, with DIVA and recombinant vaccines at USD 4.50-8.75 per dose.
Key Developments
- November 2024: Boehringer Ingelheim announced EU regulatory approval of a next-generation DIVA-compliant chimeric vaccine stable at 25°C for 18 months.
- August 2024: Hipra launched Phase 3 trials of a nanoparticle-based CSF vaccine, potentially approved in Europe and Asia by 2027.
Table of Contents
Explore the chapters covered in the full report.
Chapter 1. Report Introduction
- 1.1 Report Description
- 1.1.1 Purpose of the Report
- 1.1.2 USP & Key Offerings
- 1.2 Key Benefits For Stakeholders
- 1.3 Target Audience
- 1.4 Report Scope
Chapter 2. Market Overview
- 2.1 Market Definition & Scope
- 2.2 Key Market Takeaways
- 2.3 Market Snapshot
Chapter 3. Market Dynamics (DRO)
- 3.1 Drivers
- 3.2 Restraints
- 3.3 Opportunities
- 3.4 Market Trends
Chapter 4. Classical Swine Fever Vaccines Market - By Vaccine Type
- 4.1 Overview
- 4.2 Market Size & Forecast
Chapter 5. Classical Swine Fever Vaccines Market - By Delivery Method
- 5.1 Overview
- 5.2 Market Size & Forecast
Chapter 6. Classical Swine Fever Vaccines Market - By Animal Type
- 6.1 Overview
- 6.2 Market Size & Forecast
Chapter 7. Classical Swine Fever Vaccines Market - By End User
- 7.1 Overview
- 7.2 Market Size & Forecast
Chapter 8. Classical Swine Fever Vaccines Market - Regional Analysis
- 8.1 North America
- 8.2 Europe
- 8.3 Asia Pacific
- 8.4 Middle East & Africa
- 8.5 Latin America
Chapter 9. Competitive Landscape
- 9.1 Market Share Analysis
- 9.2 Company Benchmarking
- 9.3 Strategic Developments
Chapter 10. Company Profiles
- 10.1 Boehringer Ingelheim Animal Health
- 10.2 Merial (Zoetis Subsidiary)
- 10.3 Ceva Santé Animale
- 10.4 Novacor Biotech
- 10.5 Agrovet Animal Health
- 10.6 CAHIC (China Animal Husbandry Industry Co. Ltd.)
- 10.7 Hipra (Laboratorios Hipra S.A.)
- 10.8 Intervet-Schering Plough
- 10.9 Vacsera
- 10.10 Indian Immunologicals Limited
Chapter 11. Research Methodology
- 11.1 Research Approach
- 11.2 Data Collection & Sources
- 11.3 Market Estimation & Forecasting
- 11.4 Data Validation & Triangulation
Chapter 12. Standard Report Commercials & Add-Ons
Chapter 13. List Of Figures
Chapter 14. List Of Tables
Company Listing
- Boehringer Ingelheim Animal Health
- Merial (Zoetis Subsidiary)
- Ceva Santé Animale
- Novacor Biotech
- Agrovet Animal Health
- CAHIC (China Animal Husbandry Industry Co. Ltd.)
- Hipra (Laboratorios Hipra S.A.)
- Intervet-Schering Plough
- Vacsera
- Indian Immunologicals Limited
Market Segments
Market Segmentation
- By Vaccine Type: Inactivated, Attenuated Live, Chimeric (E2/NS3-4A deletion), Recombinant/Subunit
- By Delivery Method: Intramuscular, Oral, Intranasal, Other
- By Animal Type: Domestic Swine (piglets, growing/finishing, breeding stock), Wild Boar, Other
- By End User: Livestock Farms, Animal Health Clinics, Veterinary Hospitals, Other
- North America, Europe, Asia Pacific, Middle East & Africa, Latin America
Frequently asked questions
Which region is expected to grow at the fastest CAGR?
Which region is anticipated to dominate the market in absolute terms?
What is the projected market size by the end of the forecast period?
Who are the key players in the Classical Swine Fever Vaccines market?
Need a tailored view of this market?
Ask our analysts to adapt the scope for your priority geographies, competitive set, customer segments, or strategic questions.
Request Customisation → Request a Sample